Axim Biotechnologies Inc
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin A… Read more
Axim Biotechnologies Inc (AXIM) - Total Liabilities
Latest total liabilities as of June 2025: $13.65 Million USD
Based on the latest financial reports, Axim Biotechnologies Inc (AXIM) has total liabilities worth $13.65 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Axim Biotechnologies Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Axim Biotechnologies Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Axim Biotechnologies Inc Competitors by Total Liabilities
The table below lists competitors of Axim Biotechnologies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gulf & Pacific Equities Corp
V:GUF
|
Canada | CA$28.70 Million |
|
Anacomp Inc
PINK:ANMP
|
USA | $5.09 Million |
|
GlucoTrack Inc
NASDAQ:GCTK
|
USA | $5.54 Million |
|
Total Helium Ltd
OTCQB:TTLHF
|
USA | $2.35 Million |
|
AGILENT TECH (AG8.SG)
STU:AG8
|
Germany | €5.09 Billion |
|
Mlabs Systems Bhd
KLSE:0085
|
Malaysia | RM11.48 Million |
|
Black Widow Resources Inc
V:BWR
|
Canada | CA$1.27 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Axim Biotechnologies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Axim Biotechnologies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Axim Biotechnologies Inc (2011–2024)
The table below shows the annual total liabilities of Axim Biotechnologies Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $13.87 Million | +17.73% |
| 2023-12-31 | $11.78 Million | +30.33% |
| 2022-12-31 | $9.04 Million | +17.96% |
| 2021-12-31 | $7.66 Million | -21.41% |
| 2020-12-31 | $9.75 Million | +15.34% |
| 2019-12-31 | $8.45 Million | +3.44% |
| 2018-12-31 | $8.17 Million | -3.60% |
| 2017-12-31 | $8.48 Million | +121.86% |
| 2016-12-31 | $3.82 Million | +29.22% |
| 2015-12-31 | $2.96 Million | +124.14% |
| 2014-12-31 | $1.32 Million | +775.14% |
| 2013-12-31 | $150.74K | +9.61% |
| 2012-12-31 | $137.52K | +121.45% |
| 2011-12-31 | $62.10K | -- |